Rosuvastatin Calcium and Zenpep

• Generic Name: rosuvastatin
• Dosage Forms: n.a.
• Other Brand Names: Crestor, Ezallor Sprinkle

ACC/AHA cholesterol management guideline recommends statins as first-line therapy for prevention of atherosclerotic cardiovascular disease (ASCVD) in adults; extensive evidence demonstrates that statins can substantially reduce ASCVD risk when used for secondary prevention or primary prevention (in high-risk patients). Relative reduction in ASCVD risk is correlated with degree of LDL-cholesterol lowering; therefore, use maximum tolerated statin intensity to achieve optimum ASCVD benefits. According to ACC/AHA, rosuvastatin may be used for primary or secondary prevention in adults when moderate- or high-intensity statin therapy is indicated. (See Prevention of Cardiovascular Events under Dosage and Administration.)

Adjunct to nondrug therapies (i.e., lifestyle modifications) in patients without clinical evidence of CHD who have multiple risk factors (e.g., age, smoking, hypertension, low HDL-cholesterol concentrations, family history of early CHD) to reduce the risk of MI, stroke, or angina and the risk of undergoing revascularization procedures. Consider benefits, adverse effects, drug interactions, and patient preferences before initiating statin therapy for primary prevention.

Adjunct to dietary therapy to slow the progression of atherosclerosis as part of a treatment strategy to lower total and LDL-cholesterol concentrations to target levels.

Dyslipidemias

Adjunct to nondrug therapies (e.g., dietary management) in adults to decrease elevated serum total cholesterol, LDL-cholesterol, apolipoprotein B (apo B), non-HDL-cholesterol, and triglyceride concentrations, and to increase HDL-cholesterol concentrations in the management of primary hyperlipidemia or mixed dyslipidemia. Also used in combination with fenofibrate to decrease triglyceride concentrations and increase HDL-cholesterol concentrations in patients with mixed dyslipidemia and CHD (or CHD risk equivalents) who are on optimal statin therapy; however, no incremental benefit on cardiovascular morbidity and mortality beyond that provided by statin monotherapy.

Adjunct to nondrug therapies (e.g., dietary management) to decrease elevated serum total cholesterol, LDL-cholesterol, and apo B concentrations in the management of heterozygous familial hypercholesterolemia in children and adolescents 8–17 years of age who, despite an adequate trial of dietary management, have a serum LDL-cholesterol concentration >190 mg/dL or a serum LDL-cholesterol concentration >160 mg/dL and either a family history of premature cardiovascular disease or ≥2 other cardiovascular risk factors.

Reduction of elevated serum total cholesterol, LDL-cholesterol, and apo B concentrations in adults with homozygous familial hypercholesterolemia as an adjunct to other lipid-lowering therapies (e.g., plasma LDL-apheresis) or when such therapies are not available.

Adjunct to nondrug therapies (e.g., dietary management) to decrease elevated serum LDL-cholesterol, total cholesterol, non-HDL-cholesterol, and apo B concentrations in children and adolescents 7–17 years of age with homozygous familial hypercholesterolemia; used alone or in conjunction with other lipid-lowering therapies (e.g., LDL apheresis).

Adjunct to nondrug therapies (e.g., dietary management) for the management of hypertriglyceridemia. However, fibric acid derivatives provide greater benefit in patients with elevated triglyceride concentrations compared with statins.

Adjunct to nondrug therapies (e.g., dietary management) for the management of primary dysbetalipoproteinemia (Fredrickson type III).

Produces greater reductions in LDL-cholesterol concentrations than atorvastatin, pravastatin, or simvastatin on a mg-for-mg basis.

• Generic Name: pancrelipase
• Dosage Forms: capsule, delayed release
• Other Brand Names: Creon, Pancreaze, Pertzye, Viokace, Zenpep, Ultresa, Cotazym, Viokase, Zymase, Pancrease MT 4, Pancrease MT 16, Protilase, Panase, Ku-Zyme HP, Cotazym-S, Creon 10, Creon 20, Ultrase MT 20, Protilase MT-16, Creon 5, Pancrease, Pancrease MT 10, Vio-Moore, Panokase, Ilozyme, Pancrease MT 20, Ultrase, Ultrase MT 12, Pancron D/R, Encron-10, Ultrase MT 18, Arco-Lase, Lipram, Pancrecarb MS-8, Pancrecarb MS-4, Lipram-UL 18, Lipram-CR20, Lipram-UL 12, Lipram-UL 20, Viokase 16, Pancreatil-UL 12, Pangestyme CN 10, Pangestyme CN 20, Pangestyme MT 16, Pangestyme UL 18, Pangestyme EC, Kutrase, Ku-Zyme, Lipram-CR, Plaretase, Viokase 8, Lipram-CR5, Lapase, Dygase, Pancrecarb MS-16, Pangestyme UL 20, Panocaps, Panocaps MT 16, Lipram-CR10, Palcaps 10, Lipram-PN10, Lipram-PN16, Lipram-PN20, Panokase 16

Zenpep (pancrelipase) contains a combination of three enzymes (proteins): lipase, protease, and amylase. These enzymes are normally produced by the pancreas and are important in the digestion of fats, proteins, and sugars.

Zenpep is used to replace these enzymes when the body does not have enough of its own. Certain medical conditions can cause this lack of enzymes, including cystic fibrosis, chronic inflammation of the pancreas, or blockage of the pancreatic ducts.

Zenpep may also be used following surgical removal of the pancreas.